Study in Patients With COPD

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00215384

Enrollment

Registered

2005-09-22

Start date

Unknown

Completion date

2005-10-31

Last updated

2010-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COPD

Keywords

COPD, formoterol

Brief summary

The purpose of this study is to determine which dose of the investigational drug is the most safe and effective compared to the control drug.

Interventions

DRUGFormoterol Fumarate

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

50 Years to No maximum

Healthy volunteers

Inclusion criteria

-History of COPD and cigarette smoking

Exclusion criteria

* Clinical diagnosis of asthma. * Chest X-ray that is diagnostic of a significant pulmonary disease other than COPD * Disease of other major organ systems

Design outcomes

Primary

Measure	Time frame
The primary outcome variable is the measure of lung function.	—

Secondary

Measure	Time frame
Change in lung function will be examined as a secondary outcome, as well as vital signs, physical examination, adverse even reporting, etc.	—

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026